Navigation Links
MIGENIX Reports First Quarter Fiscal 2009 Financial Results
Date:9/15/2008

orld territories. We expect a license agreement or agreements with up-front payment(s), milestones and royalty terms to be completed after positive CLIRS trial results.

Omiganan (CLS001; topical cationic peptide; treatment of dermatological diseases): Cutanea Life Sciences ("Cutanea"), our development and commercialization partner for CLS001, is preparing to initiate its Phase III clinical program. As part of its plan to submit a NDA in 2011, Cutanea expects:

- in the first quarter of calendar 2009, to initiate chronic toxicology

studies, specifically the required dermal carcinogenicity study,

which Cutanea expects will be the rate limiting activity for

submission of the NDA; and

- in the second half of calendar 2009, to initiate its Phase III

clinical study program (previously Cutanea was targeting the end of

2008).

Celgosivir (MX-3253; oral alpha-glucosidase I inhibitor; treatment of chronic hepatitis C virus infections): Following the report of interim results from a Phase II viral kinetics study of hepatitis C virus treatment-nave patients in July 2008, we are continuing to seek strategic options for advancing the development of celgosivir and are currently in key partnering discussions.

MX-2401 (IV lipopeptide; treatment of gram-positive bacterial infections): MX-2401, an injectable lipopeptide, is being developed for the treatment of serious gram positive bacterial infections, including highly publicized treatment resistant hospital bacteria such as MRSA. We expect MX- 2401 to be our next clinical candidate as it represents a highly competitive intravenous agent for treating serious infections caused by drug-resistant bacteria for which there are currently very few effective solutions. With a view to our current financial resources, the focus of activities in this program is to increase the level of business development and scientific publication initiatives, includin
'/>"/>

SOURCE MIGENIX Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Migenix averts proxy contest; reaches agreement with DJohnson holdings
2. Notice of MIGENIX General Meeting of Shareholders
3. MIGENIX Fourth Quarter and Fiscal Year 2008 Financial Results Conference Call & Webcast Notification
4. MIGENIX Corporate Update and Requisition of Special Meeting
5. Migenix Takes Operational Actions To Extend Cash Past Upcoming Key Milestones
6. MIGENIX Appoints Pieter Dorsman to Board of Directors
7. MIGENIX Reports Third Quarter Fiscal Year 2008 Financial Results
8. MIGENIX Third Fiscal Quarter 2008 Financial Results Conference Call & Webcast Notification
9. MIGENIX releases CEO message #22
10. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
11. MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2014)... Canada Endoscopy Visualization Systems Market Outlook ... Canada Endoscopy Visualization Systems market. The report provides ... units) and average prices (in US dollars) within ... Endoscopy Visualization Systems and Low-End Endoscopy Visualization Systems. ... , The report also provides company shares and ...
(Date:7/25/2014)... July 26, 2014 "Ischemic Stroke ... 2014" provides data on the Ischemic Stroke and ... elemental information and data relating to the clinical ... View full global Ischemic Stroke Research Report 2014 ... overview of the trial numbers and their recruitment ...
(Date:7/25/2014)... Calif. , July 25, 2014 Amgen ... of Directors today declared a $0.61 per share dividend ... be paid on Sept. 5, 2014, to all stockholders ... Aug. 14, 2014.  About Amgen Amgen ... patients suffering from serious illnesses by discovering, developing, manufacturing ...
(Date:7/25/2014)... each person,s digestive tract. Scientists believe that some of ... infections, but their role in human health is not ... role of these bacteria, a team of researchers led ... in the bacterial populations of two research subjects over ... 25 issue of the journal Genome Biology , ...
Breaking Biology Technology:Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 2Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 3Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 4Canada Endoscopy Visualization Systems Market Outlook to 2020: MarketResearchReports.Biz 5Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Monitoring the rise and fall of the microbiome 2Monitoring the rise and fall of the microbiome 3
... and AALST , Belgium, AHMEDABAD, India and ... genae associates,Cardiovascular Center Aalst and J.B. Dahm, ... Core Laboratories joint venture, called imaeon., ... of medical images,analysis for clinical research projects, ...
... EDMONTON, Oct. 6 /PRNewswire-FirstCall/ - BioMS Medical ... of multiple sclerosis (MS), today,announced that the independent ... II MINDSET-01 trial of dirucotide (MBP8298) in patients,with ... recommended,that the trial continue as per the protocol., ...
... focus on a new dietary supplement resulting from years of, ... ... Del-Immune V, BOULDER, Colo., Oct. 6 On ... regulatory,cytokines Del-Immune V(R) induction and its impact on cytotoxicity of,natural killer cells" ...
Cached Biology Technology:Core Laboratories Joint Venture Agreement Between genae associates, VIBGYOR Scientific Research, Cardiovascular Center Aalst and J.B. Dahm 2BioMS Medical's relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board 2EUPROBIO 2008 Presentation to Highlight Latest Immune Research 2
(Date:7/25/2014)... novel study shows that the age girls reach puberty is ... depending on which parent contributes the gene. This is ... of development after birth and details of this study were ... of the first period, known as menarche, is a marker ... shows that the onset of menses varies between girls, is ...
(Date:7/25/2014)... researchers have detected an unknown interaction between microorganisms and ... into a droplet of salt water and is left ... create biomineralogical biosaline 3D morphologically complex formations, where they ... revived. The discovery was made by chance with a ... Astrobiology journal and may help to find ...
(Date:7/24/2014)... how wildlife loss leads to conflict among people around ... Conservation Society (WCS) Health & Ecosystems: Analysis of Linkages ... interdisciplinary approach to tackle global biodiversity decline. , The ... the world,s people and provides protein for more than ... as no surprise that today,s unprecedented loss of wildlife, ...
Breaking Biology News(10 mins):Could age of first period influence development of diseases in older women? 2Bacteria manipulate salt to build shelters to hibernate 2New study draws links between wildlife loss and social conflicts 2
... co-authored by University of Florida researchers provides details on the ... as warm summer waters attract more people to the ocean. ... print edition of Pacific Science warns that swimmers ... be considered prey. The sharks feed near the ...
... filled an important gap in the study of tunicate evolution ... free-swimming types of tunicates. Their study was featured on the ... Plankton Research . Tunicates are a phylum of animals ... called a tunic, from which the name derives. ...
... 2011 Jerusalem, Israel The Israeli Chairmanship of EUREKA, ... innovation, has released new data from a report conducted ... firm Applied Economics Ltd., to mark the completion of ... study presents the proven impact of EUREKA on companies ...
Cached Biology News:New study documents first cookiecutter shark attack on a live human 2New study documents first cookiecutter shark attack on a live human 3Woods Hole Oceanographic Institution study sheds light on tunicate evolution 2Is governmental investment in industrial R&D paying off? 2Is governmental investment in industrial R&D paying off? 3